NEO

Neogenomics
NASDAQ

实时行情|Nasdaq Last Sale

40.21
+0.25
+0.63%
交易中 13:42 08/13 EDT
开盘
39.80
昨收
39.96
最高
40.75
最低
39.80
成交量
25.63万
成交额
--
52周最高
41.03
52周最低
18.52
市值
44.40亿
市盈率(TTM)
-789.9804
分时
5日
1月
3月
1年
5年

分析师评级

8位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测NEO价格均价为40.93,最高价位45.00,最低价为39.00。

EPS

NEO 新闻

更多
NeoGenomics Slumps in Q2 but Readies for Second-Half Rebound
The oncology reference lab never stopped investing in near- and long-term opportunities. It expects that to pay off -- and soon.
Motley Fool · 08/05 15:11
The Daily Biotech Pulse: Bristol-Myers, Bluebird Bio Resubmit Multiple Myeloma Drug BLA, FSD To Close Medicinal Cannabis Business, Hologic's Blowout Quarter
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29)
Benzinga · 07/30 12:09
Neogenomics Inc (NEO) Q2 2020 Earnings Call Transcript
Joining me from our Fort Myers headquarters, with social distancing precautions in place, are Kathryn McKenzie, our Chief Financial Officer; Rob Shovlin, President of our Clinical Division; and Bill Bonello, President of our Informatics Division and Director o
Motley Fool · 07/28 17:30
Recap: NeoGenomics Q2 Earnings
Shares of NeoGenomics (NASDAQ:NEO) rose 1% after the company reported Q2 results.Quarterly Results Earnings per share fell 157.14% over the past year to ($0.04), which beat the estimate of ($0.10).Revenue of $86,977,000 decreased by 14.49% from the same period
Benzinga · 07/28 14:34
NeoGenomics (NEO) Reports Q2 Loss, Tops Revenue Estimates
NeoGenomics (NEO) delivered earnings and revenue surprises of 55.56% and 1.01%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 07/28 13:55
NeoGenomics shares are trading lower despite reporting better-than-expected Q2 EPS and sales results.
Benzinga · 07/28 11:22
NeoGenomics Q2 EPS $(0.04) Beats $(0.10) Estimate, Sales $86.98M Beat $86.12M Estimate
NeoGenomics (NASDAQ:NEO) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.10) by 60 percent. This is a 157.14 percent decrease over earnings of $0.07 per share from the same
Benzinga · 07/28 11:19
NeoGenomics Q2 2020 Earnings Preview
Seeking Alpha · 07/27 18:10

所属板块

医疗设施与服务
-0.07%
医疗保健提供商与服务
-0.74%

热门股票

代码
价格
涨跌幅

NEO 简况

NeoGenomics, Inc.是癌症基因测试实验室的运营商。该公司运营实验室测试部门。其实验室测试部门为医院、病理学家、肿瘤学家、其他临床医生和研究人员提供测试服务。该公司提供测试服务,包括细胞遗传学测试、荧光原位杂交(FISH)测试、流失细胞术测试、免疫组织化学(IHC)和数字成像。细胞遗传学测试是一项正常和异常染色体及其与疾病关系的研究。FISH测试是癌症遗传学的一个分支,专注于检测和定位染色体上特定脱氧核糖核酸(DNA)序列和基因的存在或缺失。流失细胞术测试测量细胞群体特征。数字成像是将蛋白质定位在组织切片细胞中的过程,并且依赖于在生物组织中抗体特异性结合抗原的原理。
展开

微牛提供NeoGenomics, Inc.(NASDAQ-NEO)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的NEO股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易NEO股票基本功能。